Biotron Limited (ASX:BIT)
0.0020
+0.0005 (33.33%)
Nov 20, 2026, 1:49 PM AEDT
Biotron Revenue
In the fiscal year ending June 30, 2026, Biotron had annual revenue of 525.87K AUD, down -71.00%. Biotron had revenue of 525.87K in the half year ending June 30, 2026. That makes Biotron the 44,906th largest company in the world by revenue and 1,077th in Australia.
Revenue
525.87K
Revenue Growth
-71.00%
P/S Ratio
7.94
Revenue / Employee
175.29K
Employees
3
Market Cap
5.57M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 525.87K | -1.29M | -71.00% |
| Jun 30, 2025 | 1.81M | 168.51K | 10.24% |
| Jun 30, 2024 | 1.65M | 213.83K | 14.94% |
| Jun 30, 2023 | 1.43M | -127.24K | -8.16% |
| Jun 30, 2022 | 1.56M | 96.58K | 6.61% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Acrux | 6.58M |
| Tissue Repair | 2.99M |
| Vectus Biosystems | 2.77M |
| Cynata Therapeutics | 1.71M |
| Cambium Bio | 1.23M |
| Bio-Gene Technology | 1.08M |
| Nexalis Therapeutics | 1.07M |
| AdAlta | 404.25K |